Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: A pharmacokinetic-pharmacodynamic analysis

British Journal of Anaesthesia

Volumn 89, Issue 3, 2002, Pages 428-437

  Johnson, T N ^a   Rostami Hodjegan, A ^a   Goddard, J M ^b   Tanner, M S ^a   Tucker, G T ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Anaesthesia, paediatric; Hypnotics benzodiazepine, midazolam; Pharmacodynamics; Pharmacokinetics, midazolam; Sedation, preoperative

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CARBAMAZEPINE; DRUG METABOLITE; INHALATION ANESTHETIC AGENT; MIDAZOLAM; PROPOFOL; THIOPENTAL;

AGE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHILD; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; LOGISTIC REGRESSION ANALYSIS; PEDIATRIC SURGERY; PHARMACOLOGICAL PARAMETERS; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SCORING SYSTEM; SEDATION; SURGICAL TECHNIQUE; WEIGHT;

EID: 0036041107     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/89.3.428     Document Type: Article

References (60)

1. The pharmacokinetics of midazolam in paediatric patients
2. Premedication with midazolam in children. Effects of intranasal, rectal and oral routes on plasma midazolam concentrations
3. Pediatric pharmacodynamics of oral midazolam syrup
4. The pharmacokinetics of midazolam in man
5. Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites
6. Pharmacokinetic-pharmacodymamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers
7. Pharmacokinetics of midazolam during continuous infusion in critically ill neonates
8. Population pharmacokinetics of midazolam in neonates
9. Steady state plasma concentrations of midazolam in critically ill infants and children
10. Analysis of midazolam and metabolites in plasma by high performance liquid chromatography: Probe of CYP3A
11. Maximum likelihood from incomplete data via the EM algorithm
12. A two step iterative algorithm for estimation in nonlinear mixed effect models with an evaluation in population pharmacokinetics
13. Does age alter the pharmacokinetics of midazolam and 1-OH-midazolam in paediatric patients?
14. Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: A PK-PD modeling analysis
15. Application of Akaike's information criteria (AIC) in the evaluation of linear pharmacokinetic equations
16. How many patients and blood levels are necessary for population pharmacokinetic analysis
17. Design and power of a population pharmacokinetic study
18. Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation
19. Multicompartmental models
20. Pharmacokinetic and pharmacodynamic study of midazolam in children during esophagogastroduodenoscopy
21. A comparison of three induction agents in paediatric anaesthesia-cardiovascular effects and recovery
22. Pharmacokinetics of midazolam in children: Comparative study of intranasal and intravenous administration
23. The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration
24. Oral first pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism
25. Prediction of midazolam (MDZ) clearance (CL) using minimised sampling (MS) of 1-OHM and 1-OHM/MDZ in healthy subjects (HS)
26. In vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration
27. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
28. Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes
29. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples
30. Interindividual variance of cytochrome P450 forms in human hepatic microsomes: Correlation of individual forms with xenobiotic metabolism and implications in risk assessment
31. Carbamazepine: A 'blind' assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems
32. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes
33. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics
34. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes
35. Characterization of Phase I and Phase II hepatic drug metabolism activities in a panel of human liver preparations
36. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers
37. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism
38. Enterocytic CYP3A4 in a paediatric population: Developmental changes and the effects of coeliac disease and cystic fibrosis
39. Sequences of intestinal and hepatic cytochromes P450 3A4 cDNAs are identical
40. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study
41. Pharmacokinetics of a single dose midazolam in children
42. Carbamazepine clearance in paediatric epilepsy patients
43. Liver volume as a determinant of drug clearance in children and adolescents
44. Liver volume in children measured by computer tomography
45. Human cytochrome P450 maximal activities in pediatric versus adult liver
46. Clinical pharmacology of midazolam in infants and children
47. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: Midazolam and alpha-OH-midazolam
48. Auditory and electroencephalographic effects of midazolam and alpha-hydroxy-midazolam in healthy subjects
49. Relationship between plasma concentration and effect of midazolam after oral and intravenous administration
50. Ontogeny of the benzodiazepine receptor in human brain, fluorographic, immunochemical and reversible binding studies
51. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone
52. The antitussive effect of dextromethorphan in relation to CYP2D6 activity
53. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation
54. Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects
55. Simultaneous modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepam
56. A double-blind, randomized comparison of IV lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model
57. Comparison of chloral hydrate and midazolam by mouth as premedicants in children ungergoing otolaryngological surgery
58. Oral midazolam is an effective premedication for children having day stay anaesthesia
59. Premedication of children with oral midazolam